BioSpace News Archive

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that shares of its common stock will trade on the Nasdaq Capital Market on Friday, November 11, 2022 under the ticker symbol “SCLX”.

BioGX announced that the US FDA has updated their original Direct Sample Xfree™ COVID-19 Emergency Use Authorization to increase the shelf-life of the assay reagent to 15 months and expand its use to additional real-time PCR platforms, including BioGX’s pixl™ real-time PCR platform.

Inventiva reported its cash position as of September 30, 2022 and its revenues for the first nine months of 2022.

Neovasc Inc. reported financial results for the third quarter ended September 30, 2022.

Athira Pharma, Inc. announced the company’s financial results for the third quarter ended September 30, 2022 and reviewed recent clinical and corporate updates.

Hyperfine, Inc., the creator of Swoop®, the world’s first FDA-cleared portable MRI system™, reported financial results for the quarter ended September 30, 2022 and provided a business update.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced its financial results for the three and nine months ended September 30, 2022 and provided a business update.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that it has terminated the Tollovid™ products license and distribution agreement it had with T-Cell Protect Hellas S.A.

After the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by the European Commission, as a booster for the prevention of COVID-19 in adults 18 years of age and older.

The global actinic keratosis treatment market size is expected to be worth around US$ 10.12 billion by 2030, according to a new report by Vision Research Reports.